Development, Optimization and In Vitro Evaluation of Buccal Tablet of Posaconazole

Buccal route of administration has many advantages such as improving patient compliance, bypassing the GIT and hepatic first pass effect. The objectives are to formulate Mucoadhesive buccal tablet using Posaconazole and compatible excipients, and to evaluate the product using quality control tests and in vitro tests. In the development of buccal tablet of antifungal drug Posaconazole to treat oral thrush locally and to improve the solubility and bioavailability of drug, simultaneously enhances the erosion rate of tablet Mucoadhesive dosage forms have long been employed to improve the bioavailability of drugs undergoing significant hepatic first-pass metabolism and control the release of drugs from hydrophilic matrices. Therefore, it is needed to develop suitable controlled release Mucoadhesive buccal tablets containing an antifungal agent, Posaconazole. The present study has been planned to formulate the Mucoadhesive buccal tablets of posaconazole by using xanthan gum and carbopol 940. This formulation used for the treatment of oral candidiasis. In vitro drug release results of all the formulations were conducted for 12 h which indicated that, tablet formulations, F1- F9 were found to be following non- fickian diffusion. The formulation F5 was taken as an optimized batch. Stability studies were conducted at 400C and 75 % RH as per ICH guidelines.